Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda.
Despite the potential benefit of primaquine in reducing Plasmodium falciparum transmission and radical cure of Plasmodium vivax and Plasmodium ovale infections, concerns over risk of hemolytic toxicity in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd) have hampered its deployment. A cross-sectional survey was conducted in 2014 to assess the G6PDd prevalence among 631 children between 6 and 59 months of age in southwestern Uganda, an area where primaquine may be a promising control measure. G6PDd prevalence was determined using three detection methods: a quantitative G6PD enzyme activity assay (Trinity Biotech®G-6-PDH kit), a qualitative point-of-care test (CareStart™G6PD rapid diagnostic test [RDT]), and molecular detection of the G6PD A- G202A allele. Qualitative tests were compared with the gold standard quantitative assay. G6PDd prevalence was higher by RDT (8.6%) than by quantitative assay (6.8%), using a < 60% activity threshold. The RDT performed optimally at a < 60% threshold and demonstrated high sensitivity (≥ 90%) and negative predictive values (100%) across three activity thresholds (below 60%, 30%, and 40%). G202A allele frequency was 6.4%, 7.9%, and 6.8% among females, males, and overall, respectively. Notably, over half of the G202A homo-/hemizygous children expressed ≥ 60% enzyme activity. Overall, the CareStart™G6PD RDT appears to be a viable screening test to accurately identify individuals with enzyme activities below 60%. The low prevalence of G6PDd across all three diagnostic modalities and absence of severe deficiency in our study suggests that there is little barrier to the use of single-dose primaquine in this region.
Yale School of Public Health, New Haven, Connecticut.|University of California, San Francisco, California.
Michelle E
ME
Roh
Mbarara University of Science and Technology, Mbarara, Uganda.
Caesar
C
Oyet
Mbarara University of Science and Technology, Mbarara, Uganda.|Médecins sans Frontières Epicentre, Mbarara Research Centre, Mbarara, Uganda.
Patrick
P
Orikiriza
Yale School of Public Health, New Haven, Connecticut.
Martina
M
Wade
Mbarara University of Science and Technology, Mbarara, Uganda.|Médecins sans Frontières Epicentre, Mbarara Research Centre, Mbarara, Uganda.
Juliet
J
Mwanga-Amumpaire
Mbarara University of Science and Technology, Mbarara, Uganda.|Médecins sans Frontières Epicentre, Mbarara Research Centre, Mbarara, Uganda.
Yap
Y
Boum
Mbarara University of Science and Technology, Mbarara, Uganda.
Gertrude N
GN
Kiwanuka
Yale School of Public Health, New Haven, Connecticut. sunil.parikh@yale.edu.
Sunil
S
Parikh
D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003955:Diagnostic Tests, Routine / Q000379:methods*; D005260:Female; D005787:Gene Frequency; D005954:Glucosephosphate Dehydrogenase / Q000097:blood / Q000235:genetics; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000175:diagnosis* / Q000469:parasitology; D006801:Humans; D007223:Infant; D008288:Malaria / Q000188:drug therapy; D016778:Malaria, Falciparum / Q000188:drug therapy; D016780:Malaria, Vivax / Q000188:drug therapy; D008297:Male; D019095:Point-of-Care Systems; D015995:Prevalence; D011319:Primaquine / Q000627:therapeutic use; D012424:Rural Population; D012680:Sensitivity and Specificity; D014454:Uganda; D014505:Urban Population
D005954:Glucosephosphate Dehydrogenase; C482910:glucose-6-phosphate dehydrogenase A-; D011319:Primaquine
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87
18165478
Eur J Hum Genet. 2009 Aug;17(8):1080-5
19223928
Malar J. 2012 Oct 30;11:360
23130957
PLoS One. 2014 Dec 26;9(12):e116143
25541721
Transl Res. 2015 Jun;165(6):677-88
25312015
PLoS One. 2011;6(12):e28357
22164279
Hematol Oncol Clin North Am. 2016 Apr;30(2):373-93
27040960
PLoS One. 2016 Mar 24;11(3):e0151898
27010542
BMC Res Notes. 2014 Jun 18;7:372
24943486
Emerg Infect Dis. 2016 Aug;22(8):1494-8
27434741
Malar J. 2011 May 18;10:132
21592332
Malar J. 2013 Jun 19;12:210
23782846
Am J Trop Med Hyg. 2014 Jul;91(1):77-80
24778197
PLoS One. 2009 Sep 30;4(9):e7246
19789650
Nat Commun. 2012;3:1237
23212366
BMC Med Genet. 2014 Sep 09;15:93
25201310
Malar J. 2014 Jul 11;13:270
25015414
PLoS One. 2015 Apr 17;10(4):e0125796
25885097
PLoS Negl Trop Dis. 2016 Feb 19;10(2):e0004457
26894297
Malar J. 2013 Mar 27;12:112
23537118
Malar J. 2013 Nov 04;12:391
24188096
Blood. 2012 Nov 15;120(20):4123-33
22993389
Malar J. 2014 Nov 03;13:418
25363455
Bull World Health Organ. 1989;67(6):601-11
2633878